NewLink Genetics to Present at the Credit Suisse 2013 Healthcare Conference

AMES, IA--(Marketwired - November 06, 2013) - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink’s Founder and Chief Executive Officer, is scheduled to present at the Credit Suisse 2013 Healthcare Conference in Phoenix, Arizona on Tuesday, November 12, 2013 at 5:00 p.m. ET. Interested parties may access a live webcast of the presentation by visiting the NewLink Genetics website at www.linkp.com. The webcast will be archived on the NewLink website following the event.

About NewLink Genetics Corporation

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink’s portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink’s product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.